Asklepios BioPharmaceutical, Inc. (AskBio), an independently operated subsidiary of Bayer AG, has appointed two industry veterans to advance clinical operations and lead corporate communications. Doug Schantz will serve as the Senior Vice President of Clinical Operations and will work to ensure clinical trials are executed expeditiously, in full regulatory compliance and to the highest quality standard. Phil McNamara will serve as Vice President of Communications, responsible for all internal and external communications and media relations.
 
“Doug and Phil bring a wealth of experience to the AskBio team and are reflective of the quality of individual talent we have at the company,” said Phil Dana, Chief Human Resources Officer. “Both represent key hires for AskBio as we continue to advance our pipeline and establish our position as a global leader in genetic medicine.”
 
Doug Schantz is a seasoned clinical operations expert in the biotechnology and pharmaceutical industry. He joins the company from Alexion Pharmaceuticals where he most recently served as Vice President and Head of Clinical Operations. At Alexion, he was responsible for program leadership across all phases of clinical development in several therapeutic areas, including hematology, metabolic diseases, neuroscience, and nephrology. Prior experience was with AstraZeneca as the Executive Director of Development Operations, as well as successfully serving a 17-year stint at Pfizer and eight years with Eli Lilly.
 
Phil McNamara the company from Novartis where he led Global Communications for its Cardio-Renal-Metabolic Franchise. He successfully built and led a team that supported various facets of the business and helped to enable a favorable market standing with patient and professional communities. Prior to Novartis, Mr. McNamara held global and US communication roles at Sanofi and Bristol Myers Squibb, respectively, and collectively brings over 20 years of diverse strategic communications experience to AskBio.